Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
6.25
-0.24 (-3.70%)
At close: Dec 2, 2025, 4:00 PM EST
6.30
+0.05 (0.80%)
After-hours: Dec 2, 2025, 7:00 PM EST
ARCT Employees
As of December 31, 2024, Arcturus Therapeutics Holdings had 176 total employees, including 174 full-time and 2 part-time employees. The number of employees decreased by 4 or -2.22% compared to the previous year.
Employees
176
Change (1Y)
-4
Growth (1Y)
-2.22%
Revenue / Employee
$554,551
Profits / Employee
-$379,028
Market Cap
177.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 176 | -4 | -2.22% |
| Dec 31, 2023 | 180 | 10 | 5.88% |
| Dec 31, 2022 | 170 | -7 | -3.95% |
| Dec 31, 2021 | 177 | 59 | 50.00% |
| Dec 31, 2020 | 118 | 30 | 34.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARCT News
- 8 days ago - Arcturus Therapeutics to Attend Upcoming Investor Conference - Business Wire
- 22 days ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress - Business Wire
- 4 weeks ago - Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
- 5 weeks ago - Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 - Business Wire
- 5 weeks ago - Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture - Benzinga
- 5 weeks ago - Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results - Invezz
- 5 weeks ago - Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program - Business Wire